全文获取类型
收费全文 | 1008篇 |
免费 | 75篇 |
国内免费 | 30篇 |
专业分类
儿科学 | 61篇 |
妇产科学 | 15篇 |
基础医学 | 80篇 |
口腔科学 | 48篇 |
临床医学 | 115篇 |
内科学 | 184篇 |
皮肤病学 | 13篇 |
神经病学 | 16篇 |
特种医学 | 254篇 |
外科学 | 146篇 |
综合类 | 18篇 |
预防医学 | 31篇 |
眼科学 | 4篇 |
药学 | 43篇 |
肿瘤学 | 85篇 |
出版年
2024年 | 2篇 |
2023年 | 2篇 |
2021年 | 7篇 |
2020年 | 2篇 |
2019年 | 11篇 |
2018年 | 24篇 |
2017年 | 13篇 |
2016年 | 11篇 |
2015年 | 13篇 |
2014年 | 24篇 |
2013年 | 20篇 |
2012年 | 19篇 |
2011年 | 28篇 |
2010年 | 46篇 |
2009年 | 29篇 |
2008年 | 27篇 |
2007年 | 44篇 |
2006年 | 26篇 |
2005年 | 18篇 |
2004年 | 12篇 |
2003年 | 20篇 |
2002年 | 17篇 |
2001年 | 19篇 |
2000年 | 12篇 |
1999年 | 15篇 |
1998年 | 60篇 |
1997年 | 71篇 |
1996年 | 78篇 |
1995年 | 49篇 |
1994年 | 40篇 |
1993年 | 43篇 |
1992年 | 17篇 |
1991年 | 12篇 |
1990年 | 19篇 |
1989年 | 39篇 |
1988年 | 40篇 |
1987年 | 30篇 |
1986年 | 30篇 |
1985年 | 31篇 |
1984年 | 8篇 |
1983年 | 10篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 13篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1950年 | 1篇 |
排序方式: 共有1113条查询结果,搜索用时 0 毫秒
121.
Sonoelasticity imaging of prostate cancer: in vitro results 总被引:2,自引:0,他引:2
122.
J M Schafer E S Lee R C Dardes D Bentrem R M O'Regan A De Los Reyes V C Jordan 《Clinical cancer research》2001,7(8):2505-2512
PURPOSE: Cross-resistance is the primary issue facing the evaluation of new antiestrogens to treat metastatic breast cancer because they may be tested, initially, in populations of patients that have failed long-term adjuvant tamoxifen (Tam) therapy. EXPERIMENTAL DESIGN: We have tested the benzothiophene derivatives, arzoxifene (Arzox; LY353381) and LY117018 in two models of Tam-stimulated tumor growth derived from either MCF-7 (M. M. Gottardis and V. C. Jordan, Cancer Res., 48: 5183-5187, 1988) or T47D (J. MacGregor Schafer et al., Clin. Cancer Res., 6: 4373-4380, 2000) breast cancer cells. RESULTS: Using the MCF-7:Tam model, we found that both Arzox and LY117018 (1.5 mg/day) resulted in tumor growth and, therefore, were partially cross-resistant with Tam. Next, using the T47D:17beta-estradiol (E(2)) model, we compared the antiestrogenic/antitumor properties of Arzox and LY117018 and determined that neither Arzox nor LY117018 caused T47D:E(2) tumor growth after 21 weeks. In addition, we determined that long-term treatment does not result in failure and subsequent development of transplantable Arzox- or LY117018-stimulated tumors. To establish whether Arzox and LY117018 are cross-resistant in T47D:Tam tumors, mice were treated with Arzox or LY117018 (1.5 mg/day), and, again, we found that neither resulted in the growth of transplantable tumors. Lastly, we showed that Arzox and LY117018 were only partially able to compete with postmenopausal E(2) (0.3 cm silastic capsule) in T47D:Tam tumors. However, when T47D:E(2) tumors were treated for 7 days instead of 5 days, both Arzox and LY117018 were more effective. CONCLUSIONS: Arzox is not cross-resistant with Tam in the T47D athymic mouse model but does exhibit cross-resistance in the MCF-7 model. 相似文献
123.
A retrospective analysis was made of the data on 60 patients with stage T1 glottic carcinoma (43 T1a, 17 T1b) who received radiation therapy and 17 patients with T1a disease who underwent laser excision as the primary treatment modality. Patients who received radiation therapy achieved 3- and 5-year actuarial local control rates of 92% and 89% for T1a and 77% and 77% for T1b disease, respectively. In patients who underwent laser excision (all with T1a disease), the 3-year local control rate was 77%. Of the 42 evaluable irradiated T1a patients, 31 (74%) had a normal to near-normal voice, eight (19%) had mild or intermittent hoarseness, and three (7%) had persistent hoarseness. Of the 13 evaluable patients in the laser-excision group, four (31%) had a normal to near-normal voice, five (38%) had mild or intermittent hoarseness, and four (31%) had persistent hoarseness. The difference in the quality of voice between these two groups is statistically significant (P = .012), although the ultimate local control rate after salvage therapy for irradiated patients (97%) was similar to that for laser-excision patients (94%). 相似文献
124.
125.
Krutchen AE; Bjarnason H; Stackhouse DJ; Nazarian GK; Magney JE; Hunter DW 《Radiology》1996,200(1):159
126.
ST O'Sullivan MD FRCSI GT McGreal FRCS CM Reardon FRCSI DJ Hehir MCH FRCSI WO Kirwan MCH FRCSI MP Brady MCH FRCSI 《International journal of clinical practice》1997,51(5):289-292
During a four-year period, 308 patients presented following ingestion of foreign bodies. Ingestion was accidental in 272 cases (88.3%) and deliberate in the remainder. Symptoms at presentation included dysphagia, odynophagia, nausea and vomiting, chest pain and pharyngeal discomfort. Sixty-eight patients were asymptomatic. A policy of expectant management and selective endoscopy was employed. Following initial assessment 202 patients (65.6%) were discharged without treatment, 30 (9.7%) of whom were later reviewed as outpatients and did not require admission. Forty-nine patients (16%) were admitted for treatment; 27 had oesophagoscopy, five bronchoscopy and two had foreign body extraction with direct laryngoscopy. In nine patients who were endoscoped, no foreign body was identified. Twenty-seven others were referred to the otorhinolaryngology service in another hospital. There were no deaths in the group and morbidity was 1.2%. We conclude that a policy of selective endoscopy is safe and effective in the management of patients following ingestion of foreign bodies. 相似文献
127.
128.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L 《Blood》1995,86(8):2913-2921
Cumulative thrombocytopenia is a dose-limiting toxicity of dose- intensive chemotherapy for advanced breast cancer. In this phase I study, we have studied the hematologic toxicity associated with sequential interleukin-3 (IL-3) and granulocyte-macrophage colony- stimulating factor (GM-CSF; molgramostim) administration after multiple cycles of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy compared with that after concurrent cytokine administration or to each cytokine administered alone. Ninety- three patients with advanced breast cancer were treated with five cycles of FLAC chemotherapy and either IL-3 alone, GM-CSF alone, sequential IL-3 and GM-CSF administered by schedule A (5 days of IL-3 followed by 10 days of GM-CSF) or schedule B (9 days of IL-3 followed by 6 days of GM-CSF), or concurrent administration of IL-3 and GM-CSF for 15 days. Cohorts of patients were treated with one of four dose levels of IL-3 (1,2.5, 5, and 10 micrograms/kg) administered subcutaneously for each schedule of cytokine administration. The GM-CSF dose in all schedules was 5 micrograms/kg/day. Sequential IL-3 and GM- CSF (schedule B) was associated with higher platelet nadirs, shorter durations of platelet counts less than 50,000/microL, and the need for fewer platelet transfusions over five cycles of FLAC chemotherapy compared with concurrent cytokines, sequential IL-3 and GM-CSF schedule A, and GM-CSF alone. Concurrent IL-3 and GM-CSF was associated with unexpected platelet toxicity. The duration of granulocytopenia after FLAC chemotherapy was significantly worse with IL-3 alone compared with each of the GM-CSF-containing cytokine regimens. Although no cycle 1 maximum tolerated dose for IL-3 was defined in this study, 5 micrograms/kg was well tolerated over multiple cycles of therapy and is recommended for future studies. The data from this phase I study suggest that sequential IL-3 and GM-CSF with IL-3 administered for 9 days before beginning GM-CSF may be superior to shorter durations of IL- 3 administered sequentially with GM-CSF, to concurrent IL-3 and GM-CSF, and to either colony-stimulating factor alone in ameliorating the cumulative hematologic toxicity associated with multiple cycles of FLAC chemotherapy. Additional studies of sequential IL-3 and GM-CSF are warranted. 相似文献
129.
Pharmacokinetics of midazolam in Vietnamese subjects 总被引:2,自引:0,他引:2
KR BALSON DJ MORGAN BH RICHMOND ME McALINDON SL ELLIOTT ND YEOMANS 《Journal of gastroenterology and hepatology》1996,11(10):1177-1180
130.
Kohli-Kumar M; Morris C; DeLaat C; Sambrano J; Masterson M; Mueller R; Shahidi NT; Yanik G; Desantes K; Friedman DJ 《Blood》1994,84(6):2050-2054
Eighteen patients with Fanconi anemia (FA) with evidence of bone marrow (BM) aplasia underwent allogenic BM transplants (BMT) from matched sibling donors (MSD). Median age at BMT was 7.6 years. Conditioning consisted of low-dose cyclophosphamide (CY; 5 mg/kg x 4 days) and thoracoabdominal irradiation (TAI; 400 cGy). Graft-versus-host disease (GVHD) prophylaxis included cyclosporin A and prednisone. In addition antithymocyte globulin (ATG) was administered in the pretransplant period to promote engraftment and in the posttransplant period for additional GVHD prophylaxis. Engraftment occurred rapidly (median, 12 days for an absolute neutrophil count > or = 0.5 x 10(9)/L; median, 22 days for platelet count > or = 50 x 10(9)/L). Seventeen patients have sustained engraftment and are transfusion-independent, with Lansky scores of 100% at median follow-up of 27 months. One patient developed graft failure 4 months after initial engraftment and required a second BM infusion. None of the patients developed acute GVHD; 3 patients (16%) developed chronic GVHD. BMT is a feasible option for FA patients having an MSD and should be performed at a young age and early in the course of the disease, before the development of complications. We believe the addition of ATG to the transplant regimen of low-dose CY, TAI, and cyclosporin was responsible for improvement in the survival of FA patients undergoing BMT. The regimen was well tolerated and was associated with a low incidence of complications including GVHD. 相似文献